Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.59 |
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233 | 0.90 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2234 | 0.90 | AGTR1 (0.71) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8383041 | 0.89 | AGTR1 (0.58) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2251 | 0.87 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL29669823 | 0.87 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2373 | 0.87 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2252 | 0.87 | AGTR1 (0.73) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL683473 | 0.87 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL7269293 | 0.87 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL8242346 | 0.87 | AGTR1 (0.58) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | disclosed |
| US-7659406-B2 | Process for preparing valsartan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-02-09 | — | — | US | disclosed |
| US-7361770-B2 | Process for preparation of valsartan | HETERO DRUGS LIMITED (IN) | 2008-04-22 | — | — | US | disclosed |
| WO-2004111018-A1 | A NOVEL PROCESS FOR PREPARATION OF VALSARTAN | HETERO DRUGS LIMITED (IN) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | REN, AGT, ACE | AGTR1 6/4885LTB4R2 2598/4885ABCB11 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.